Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Iodine i 131"'
Autor:
Leo I. Gordon, Andrew M. Evens
Publikováno v:
Clinical Lymphoma. 5:S11-S15
The treatment for non-Hodgkin's lymphoma (NHL) has improved over the past 20 years, but the natural history of the disease has not improved with conventional therapeutics. New modalities using targeted therapy based on molecular biology and immunolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a77bfdd95ed0e3929a9cdd84b15919f6
https://doi.org/10.3816/clm.2004.s.003
https://doi.org/10.3816/clm.2004.s.003
Autor:
Patricia Giampietro, Vanessa C. Williams, Thomas S. Lin, Robert C. Quackenbush, Thierry Horner
Publikováno v:
Leukemia & Lymphoma. 56:779-781
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e0fb3515d1c1a15f9b5ecf3c0066e61
https://doi.org/10.3109/10428194.2014.927461
https://doi.org/10.3109/10428194.2014.927461
Autor:
Peter V. Scrivani, Hollis N. Erb, Nathan L. Dykes, Jeff M. Hobbs, Lorna J. Hubble, Heather J. Chalmers
Publikováno v:
American Journal of Veterinary Research. 68:354-357
Objective—To assess agreement between a commercially available Geiger-Meuller (GM) survey meter and millirem tissue-equivalent (TE) meter for measuring radioactivity in cats treated with sodium iodine I 131 (131I). Animals—15 cats with hyperthyro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43cb6ce2963bc2d0bff745e077c9896
https://doi.org/10.2460/ajvr.68.4.354
https://doi.org/10.2460/ajvr.68.4.354
Autor:
Stanley J. Goldsmith, Shankar Vallabhajosula, Richard R. Furman, Amy Chadburn, Daniel Muss, Jodi V Mones, Morton Coleman, Patricia Stewart, Lale Kostakoglu, Tsiporah B. Shore, John P. Leonard, Stewart Kroll
Publikováno v:
Leukemia & Lymphoma. 48:342-348
Radioimmunotherapy (RIT) with tositumomab and iodine 131 tositumomab can produce durable and complete responses in relapsed/refractory low-grade Non-Hodgkin's lymphoma. Patients with bone marrow involvement (BMI) with tumor25% of the intertrabecular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de6f2689ea9d7cc45953ffd4357480b
https://doi.org/10.1080/10428190601059720
https://doi.org/10.1080/10428190601059720
Autor:
Brad Pohlman, Roger M. Macklis
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 66:833-841
Purpose: The aim of this study was to review advances in radioimmunotherapy (RIT) for non-Hodgkin's lymphoma (NHL) and to discuss the role of the radiation oncologist in administering this important new form of biologically targeted radiotherapy. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3788f059a81a124c15339d34a667e441
https://doi.org/10.1016/j.ijrobp.2006.05.030
https://doi.org/10.1016/j.ijrobp.2006.05.030
Autor:
Stewart M. Kroll, Melissa Tuck, Richard L. Wahl, Paul V. Kison, Mark S. Kaminski, Judith Estes, Kenneth R. Zasadny, Denise Regan, Arne Kolstad, Susan J. Fisher, Charles W. Ross
Publikováno v:
New England Journal of Medicine. 352:441-449
Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in previously un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6936078be04ae197089b6346355774d0
https://doi.org/10.1056/nejmoa041511
https://doi.org/10.1056/nejmoa041511
Publikováno v:
Clinical Lymphoma. 5:S5-S10
Because of their remarkable effectiveness in radioimmunotherapy (RIT), 2 anti-CD20 monoclonal antibody (MAb) drugs, one labeled with indium 111 for imaging or yttrium 90 for therapy, and another labeled with iodine I 131 for imaging and therapy, have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7769156fff3755ff7f8c11c41a25ea3c
https://doi.org/10.3816/clm.2004.s.002
https://doi.org/10.3816/clm.2004.s.002
Autor:
Jane N. Winter
Publikováno v:
Clinical Lymphoma. 5:S22-S26
Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c306c60a69ee6cd1e072275409fdd8
https://doi.org/10.3816/clm.2004.s.005
https://doi.org/10.3816/clm.2004.s.005
Autor:
Ivana N. Micallef, J.A. Lawrance, Maggie A Harris, H. Jan, T. A. Lister, S.J. Mather, Keith E. Britton, J. A. L. Amess, S Owens, John Radford, D.P. Deakin, Simon J Howell, B.M. Carrington, A. Z. S. Rohatiner, Andrew Davies, S. Kroll, J Clayton, R. Foley, Andrew J. Norton, Sarah Vinnicombe
Publikováno v:
Journal of Clinical Oncology. 22:1469-1479
PurposeAn open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma.Patients and MethodsA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e98c1152e0a2902f06cb97c53f9f9b08
https://doi.org/10.1200/jco.2004.06.055
https://doi.org/10.1200/jco.2004.06.055
Autor:
Julie M. Vose
Publikováno v:
The Oncologist. 9:160-172
Learning Objectives After completing this course, the reader will be able to: Describe advances in clinical radioimmunotherapy. Discuss ongoing translational research in radioimmunotherapy. Identify future directions for radioimmunotherapy in cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f12176e71e7c25fff5e942f909428604
https://doi.org/10.1634/theoncologist.9-2-160
https://doi.org/10.1634/theoncologist.9-2-160